SeaBeLife: SeaBeLife's SBL01 acute liver failure drug candidate receives ODD from the EMA
The small molecule acts as a necrosis and ferroptosis inhibitor, allowing for the protection and restoration of liver cells in those with acute liver failure
Read full article »
SeaBeLife is a France-based biotechnology company that researches and develops small molecules for the treatment of regulated necrosis.
Read more